arrow
M

Maria-Pilar Barretina-Ginesta

institut català d’oncologia and girona biomedical research institute and university of girona
H指数:16
被引数:1,511

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multidisciplinary management of advanced ovarian cancer in Spain: expert recommendations for achieving maximum survival and improving patient care

西班牙高级别卵巢癌的多学科管理:实现最大生存率和改善患者护理的专家建议

2026-07-060
OAAI
Morphological and molecular characterization of epithelial ovarian cancer: SEOM-SEAP consensus guidelines for biomarker integration in clinical practice

上皮卵巢癌的形态学和分子学特征:SEOM-SEAP关于生物标志物整合的临床实践共识指南

2026-05-010
PRE
Long-Term Young Adult Cancer Survivors with Ovarian Cancer: Subgroup Analysis of the Study “Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer”: The International NOGGO, ENGOT, and GCIG Survey

长期年轻成年卵巢癌幸存者:研究“Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer”的亚组分析:国际NOGGO、ENGOT和GCIG调查

Cancers
IF4.4
2026-04-080
OAAI
Addressing unmet needs in long-term survivors of ovarian cancer (ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI): insights from a Spanish cohort

探讨卵巢癌长期生存者中未满足需求的研究(ENGOT ov40/NOGGO S13/GEICO 71-R/Expression VI):来自西班牙队列的见解

2026-01-070
PRE
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer

关于晚期卵巢癌维持治疗方案选择和护理模式的驱动因素共识

2025-04-190
OA
Tolerability of the niraparib individualized starting dose in the PRIMA/ ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy

尼拉帕利一线维持治疗的PRIMA/ ENGOT-OV26/GOG-3012试验中尼拉帕利个体化起始剂量的耐受性

2024-09-011
PRE
Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

PRIMA试验中无疾病或毒性症状的质量调整时间和尼拉帕尼维持治疗一线卵巢癌的质量调整无进展生存期

2022-09-226
OAAI
Impact of pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) on overall survival (OS) in patients (p) with metastatic castration-sensitive prostate cancer (mCSPC) treated with docetaxel (D) plus androgen-deprivation therapy (ADT)
2020-09-012
OAAI
Prognostic significance of docetaxel (D) plus androgen-deprivation therapy (ADT) in patients (p) with metastatic castration-sensitive prostate cancer (mCSPC) according to extent of disease: A study of real-world data
2020-09-010
OAAI
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

同源重组缺陷的肿瘤依赖于氧化代谢: 与PARP抑制剂治疗的相关性

2020-05-1348
OAAI